Category ยท 6 peptides
Peptides for skin, hair & collagen
Topical copper peptides have genuine cosmetic data. The injectable versions? Mostly hype. Pep sorts the glow-up from the grift.

Cream beats the needle
GHK-Cu has real human cosmetic studies โ topically. Injecting it for skin has no efficacy data.
Collagen actually holds up
Oral collagen peptides are one of the few here with solid, repeated human trials.
Stacks are marketing
GLOW and KLOW bundle several peptides โ convenient, but no stack has been studied as a stack.
Every Skincare peptide we've ruled on
See all categories โCollagen peptides (hydrolyzed collagen) are short chains of amino acids taken by mouth, commonly researched for skin elasticity, hydration, and joint comfort. They are one of the few options in this space with repeated human trials behind them. They are sold as a dietary supplement, not a drug, and are not FDA-approved to treat any condition.
Copper tripeptide with real cosmetic data โ topically. The injectable form is a different, unproven story.
The GLOW stack bundles three research peptides โ GHK-Cu, BPC-157 and TB-500 โ into one vial, marketed for skin and recovery. Each part has its own separate research story, but the blend itself has never been studied as a blend, and it is not FDA-approved.
KLOW is a multi-peptide blend commonly sold for skin and recovery, combining GHK-Cu, KPV, BPC-157, and TB-500. Each part has its own separate research base, but the bundle itself has not been studied as a stack, and its components are not FDA-approved. It is sold for laboratory research use only.
Melanotan 2 (melanotan II) is a synthetic melanocortin-receptor peptide commonly researched for skin pigmentation and, separately, sexual arousal. It is not FDA-approved and is sold only for laboratory research use; regulators have repeatedly warned against human use, and dermatologists have documented real safety concerns.
Topical expression-line peptide pitched as a needle-free Botox alternative, with early cosmetic data and a real penetration caveat.